Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Temafloxacin: an overview.

G A Pankey1

  • 1Ochsner Clinic, New Orleans, Louisiana 70121.

The American Journal of Medicine
|December 30, 1991
PubMed
Summary
This summary is machine-generated.

Temafloxacin, a new fluoroquinolone antibiotic, offers broad-spectrum activity and convenient dosing for various infections. Clinical trials demonstrate its efficacy and safety in treating respiratory, urinary, and skin infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment.

Transplant infectious disease : an official journal of the Transplantation Society·2014
Same author

Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2008
Same author

Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2004
Same author

Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Deep dermatophytosis: report of 2 cases and review of the literature.

Cutis·2001
Same author

Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Practice Changing Updates in Perioperative Medicine Literature 2025. A Systematic Review.

The American journal of medicine·2026
Same journal

Risk of Infection-Related Hospitalization Is More Than Doubled in Cushing's Syndrome vs Matched Controls.

The American journal of medicine·2026
Same journal

Chronic Inflammatory Diseases and Survival among Patients with Pancreatic Cancer in the U.S. Military Health System.

The American journal of medicine·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Temafloxacin is a novel fluoroquinolone antibiotic.
  • It exhibits a favorable pharmacokinetic profile, including a 7-8 hour half-life and rapid gastrointestinal absorption.
  • This profile supports convenient oral dosing regimens.

Purpose of the Study:

  • To evaluate the antimicrobial activity and clinical efficacy of temafloxacin.
  • To assess its pharmacokinetic properties and safety profile.
  • To compare its effectiveness against other antimicrobial agents.

Main Methods:

  • In vitro susceptibility testing against various bacterial pathogens.
  • Clinical trials evaluating efficacy in treating lower respiratory tract infections, urinary tract infections, and skin/skin-structure infections.

Related Experiment Videos

  • Pharmacokinetic studies assessing tissue and body fluid penetration.

    • Main Results:

    • Temafloxacin demonstrates broad-spectrum activity against Gram-positive and Gram-negative bacteria, including enhanced in vitro activity against Streptococcus pneumoniae, Mycoplasma hominis, and Bacteroides fragilis.
    • It is as effective as beta-lactam therapy and superior to ciprofloxacin for S. pneumoniae lower respiratory infections.
    • Clinical trials show efficacy in short-term regimens for uncomplicated urinary tract infections and other common infections.

    Conclusions:

    • Temafloxacin is an effective and well-tolerated antimicrobial agent for various infections in adult patients.
    • Its pharmacokinetic properties allow for convenient once- or twice-daily oral administration.
    • Temafloxacin represents a valuable therapeutic option, particularly for infections caused by susceptible Gram-positive and Gram-negative bacteria.